Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses a session on data from several long-term studies on localized disease, including optimal sequencing of radiation and androgen-deprivation therapy; the efficacy and toxicity of SBRT; conventional vs hypofractionated radiation therapy; and dose escalation (Scientific Symposium 08).
Michael Soike, MD, of Wake Forest University Medical Center, discusses results from a large multicenter study that suggests salvage stereotactic radiosurgery leads to improved overall survival compared with whole-brain radiotherapy for patients with progressive brain metastases (Presentation 296 in Scientific Symposium 40).
Daniel R. Gomez, MD, of The University of Texas MD Anderson Cancer Center, discusses the final results of a phase II study on local consolidative therapy, which improved overall survival compared with maintenance therapy and observation in oligometastatic non–small cell lung cancer (Abstract LBA3).
Alan Pollack, MD, of the University of Miami, discusses study findings on short-term androgen-deprivation therapy with or without pelvic lymph node treatment added to prostate bed–only salvage radiotherapy (Abstract LBA5).
Vinai Gondi, MD, of Northwestern Medicine, discusses the early results of a phase III NRG Oncology trial that suggests a practice change in treating brain metastases: avoiding the hippocampus when delivering whole-brain radiotherapy (Abstract LBA9).
Howard M. Sandler, MD, of Cedars-Sinai Medical Center, summarizes a session he moderated that included discussion of an ASTRO, ASCO, and AUA guideline; indications and dose fractionation; treatment volumes; and the use of IGRT and IMRT (Panel 03).
